文献速递药物相互作用

度拉糖肽与地高辛、华法林、阿托伐他汀或复方口服避孕药联用时不推荐剂量调整

No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide.
PubMed 文献 · Clin Pharmacokinet · 2017-01-01

本文基于四项临床药理学研究,在健康受试者中评估皮下注射度拉糖肽1.5 mg对口服地高辛、华法林、阿托伐他汀及Ortho-Cyclen®药代动力学及华法林药效学的影响。结果显示除阿托伐他汀AUC降低21%外,各分析物AUC与未联用度拉糖肽时相似,Cmax普遍降低且tmax延长,华法林INRmax无统计学显著变化。结论为度拉糖肽未对上述药物吸收产生临床相关影响,不推荐剂量调整。

要点

  • 度拉糖肽1.5 mg皮下注射不推荐对地高辛、华法林、阿托伐他汀或复方口服避孕药进行剂量调整。
  • 联用度拉糖肽后各分析物Cmax普遍降低、tmax延长,但AUC除阿托伐他汀降低21%外均相似。
  • 华法林INRmax无统计学显著变化,AUCINR增加2%。

核心结论

  • 度拉糖肽未对地高辛、华法林、阿托伐他汀及Ortho-Cyclen®的吸收产生临床相关程度的影响。
  • 基于药代动力学和药效学评估,上述药物与度拉糖肽联用时无需剂量调整。

研究设计与样本

  • 四项独立的临床药理学研究。
  • 在健康受试者中口服给予地高辛、华法林、阿托伐他汀和Ortho-Cyclen®,比较联用与不联用皮下注射度拉糖肽1.5 mg的情况。
  • 基于关键分析物的药代动力学参数评估度拉糖肽联用效应,并评估度拉糖肽对华法林国际标准化比值(INR)的影响。

主要发现

  • 除阿托伐他汀AUC降低21%外,所有分析物联用与不联用度拉糖肽时的AUC相似。
  • 联用度拉糖肽后Cmax普遍降低,除R-华法林外所有分析物的几何最小二乘均值比值的90%置信区间超出0.80-1.25,具统计学显著性。
  • 所有分析物联用度拉糖肽后tmax普遍呈延长趋势。
  • 华法林联用度拉糖肽对INRmax无统计学显著影响,但观察到INR曲线下面积(AUCINR)增加2%。

关键数值与推荐

  • 阿托伐他汀AUC降低21%。
  • 除R-华法林外所有分析物Cmax降低的几何最小二乘均值比值90%置信区间超出0.80-1.25。
  • 华法林INRmax无统计学显著变化,AUCINR增加2%。
  • 不推荐对地高辛、华法林、阿托伐他汀和Ortho-Cyclen®进行剂量调整。

临床怎么用

  • 临床药师在度拉糖肽与地高辛、华法林、阿托伐他汀或复方口服避孕药联用时,无需因相互作用进行常规剂量调整。
  • 仍需关注联用后Cmax降低和tmax延长可能带来的疗效或监测时机影响,尤其对治疗窗窄的药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of type 2 diabetes mellitus are known to delay gastric emptying (GE). The potential effect of the GLP-1 RA dulaglutide on the pharmacokinetics (PK) of four orally administered drugs and on the pharmacodynamic (PD) effect of warfarin was investigated. METHODS: In four separate clinical pharmacology studies, digoxin, warfarin, atorvastatin and Ortho-Cyclen® were orally administered to healthy subjects with and without a subcutaneous dose of dulaglutide 1.5 mg. The effect of dulaglutide coadministration was assessed based on the PK parameters of key analytes. For warfarin PD, the effect of dulaglutide on the international normalized ratio (INR) was evaluated. RESULTS: Areas under the concentration-time curves (AUCs) with and without dulaglutide were similar for all analytes except atorvastatin, where it was reduced by 21%. Maximum concentrations (C max) were generally lower following coadministration with dulaglutide, with statistically significant reductions (90% confidence intervals of geometric least squares means ratios outside 0.80-1.25) for all analytes except R-warfarin. For all analytes, there was a general trend for the time to C max (t max) to increase following coadministration with dulaglutide. For warfarin, dulaglutide coadministration had no statistically significant effect on the maximum INR (INRmax); however, a 2% increase in area under the INR curve (AUCINR) was observed. CONCLUSIONS: Dulaglutide did not affect the absorption of the tested medications to a clinically relevant degree. Based on the PK and PD evaluations, no dose adjustments for digoxin, warfarin, atorvastatin and Ortho-Cyclen® are recommended when coadministered with dulaglutide. CLINICAL TRIAL REGISTRATION NUMBERS: NCT01458210, NCT01436201, NCT01432938, and NCT01250834.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. de la Peña A, Cui X, Geiser J, et al. No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. Clin Pharmacokinet. 2017. PMID: 28357715. doi:10.1007/s40262-017-0531-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。